Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.75 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373743 | 0.92 | CYP3A4 (0.81) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5365251 | 0.92 | CYP3A4 (0.81) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5368787 | 0.91 | CYP3A4 (0.80) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5377291 | 0.90 | CYP3A4 (0.79) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5372609 | 0.90 | CYP3A4 (0.91) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL5364957 | 0.86 | CYP3A4 (0.79) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL13370718 | 0.86 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL3042268 | 0.86 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL21775 | 0.86 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| Lopinavir SCHEMBL22382744 | 0.86 | CYP3A4 (1.00) | CYP3A4ABCC3ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | CYP3A4 1600/4885ABCC3 2311/4885ABCC4 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.